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ABSTRACT 51 
 52 
Prevention of central nervous system (CNS) relapse is critical for cure of childhood B-53 
cell precursor acute lymphoblastic leukaemia (BCP-ALL). Despite this, mechanisms of 54 
CNS infiltration are poorly understood and the timing, frequency and properties of 55 
BCP-ALL blasts entering the CNS compartment are unknown. We investigated the 56 
CNS-engrafting potential of BCP-ALL cells xenotransplanted into immunodeficient 57 
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ mice. CNS engraftment was seen in 23/29 diagnostic 58 
samples (79%), 2/2 from patients with overt CNS disease and 21/27 (78%) from 59 
patients thought to be CNS-negative by diagnostic lumbar puncture. Histological 60 
findings mimic human pathology and demonstrate that leukaemic cells primarily transit 61 
the blood-cerebrospinal-fluid barrier sitting in close proximity to the dural sinuses – the 62 
site of recently discovered CNS lymphatics. Retrieval of blasts from the CNS showed 63 
no evidence for chemokine receptor-mediated selective trafficking. The high frequency 64 
of infiltration and lack of selective trafficking led us to postulate that CNS tropism is a 65 
generic property of leukaemic cells. To test this we performed serial dilution 66 
experiments, CNS engraftment was seen in 5/6 mice following transplantation of as few 67 
as 10 leukaemic cells. Finally, clonal tracking techniques confirmed the polyclonal 68 
nature of CNS infiltrating cells with multiple clones engrafting in both the CNS and 69 
periphery. Overall, these findings suggest that sub-clinical seeding of the CNS is likely 70 
to be present in the majority of BCP-ALL patients at original diagnosis and efforts to 71 
prevent CNS relapse should concentrate on augmenting effective eradication of disease 72 
from this site, rather than targeting entry mechanisms.  73 
 74 
 75 
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INTRODUCTION 76 
 77 
One of the earliest advances in curative treatment for childhood acute lymphoblastic 78 
leukaemia (ALL) came with the recognition that without central nervous system (CNS) 79 
directed therapy up to 75% of children relapse within the CNS 1. Introduction of 80 
universal CNS-directed treatment resulted in a dramatic reduction in overt CNS 81 
relapses. However, disease in the CNS still poses many clinical challenges 2. CNS-82 
directed therapy is potentially toxic to the developing brain 3 and efforts to risk-stratify 83 
and devise less toxic therapy are hampered by a lack of knowledge regarding 84 
mechanisms of CNS disease and the absence of biomarkers predictive of CNS relapse.  85 
CNS involvement is classified by identification of lymphoblasts in cytospin 86 
preparations of cerebrospinal fluid (CSF); CNS-1 (CSF white cell count (WCC) <5/µl, 87 
no blasts), CNS-2 (WCC<5/µl, visible blasts) or CNS-3 (WCC>5/µl). It is important to 88 
appreciate that CNS-1 status does not equate with absence of leukaemia in the central 89 
nervous system, early post-mortem studies on children succumbing to leukaemia 90 
frequently showed leptomeningeal involvement despite negative CSF cytology 4. 91 
Cytological classification is insensitive 5-7 and clearly inadequate for risk stratification 92 
since the majority of relapses occur in CNS-1 children 8,9 In addition, the CNS is one of 93 
the major sites of relapse in children with otherwise excellent prognosis as determined 94 
by low-risk bone marrow (BM) minimal residual disease measurements 10 suggesting 95 
that factors influencing leukaemic kill in the periphery may not apply to the CNS. It is 96 
clear that a better understanding of CNS disease is required in order to develop rational 97 
risk-stratified treatment.  98 
Two possible models for CNS relapse can be postulated (see Figure 1). Firstly, it is 99 
possible that only some leukaemic cells acquire the ability to enter the CNS and the risk 100 
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of CNS relapse depends on the presence or absence of a clone with the capacity to leave 101 
the bone marrow and enter the CNS – this may occur at diagnosis or later during the 102 
disease course (model 1). Alternatively, all leukaemic cells may have the ability to seed 103 
this compartment and sub-clinical CNS involvement at diagnosis may be universal. In 104 
this case CNS relapse is determined by whether cells can adapt to the foreign 105 
microenvironment of the CNS and evade elimination by ALL-directed therapy and/or 106 
immunological surveillance (model 2). Distinguishing between these two models is 107 
critical in order to determine the optimal approaches for risk stratification, development 108 
of biomarkers and novel therapeutics to prevent CNS relapse. 109 
Here we describe experiments that test these alternative models by addressing the 110 
qualitative question of whether every leukaemic blast and/or every individual 111 
patient/subtype of leukaemia has the intrinsic capacity to enter the CNS. We 112 
demonstrate that primary BCP-ALL blasts, even from low risk CNS-1 patients, 113 
frequently infiltrate the CNS in xenograft models by transiting the Blood-CSF barrier. 114 
We find no evidence for selective trafficking of subclones to the CNS but rather show 115 
that CNS infiltration is a generic and ubiquitous property of BCP-ALL cells. These 116 
findings support the current dogma that all children require CNS-directed therapy and 117 
suggest that novel therapies to reduce the risk of CNS relapse and/or to provide safer 118 
and less toxic CNS directed therapy should concentrate on effective eradication of cells 119 
from this site rather than targeting selected entry mechanisms. 120 
 121 
MATERIALS AND METHODS 122 
 123 
Cell culture and primary cells 124 
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SD1, REH (DSMZ, Braunschweig, Germany) and Sup B15 (ATCC, LGC-standards 125 
Middlesex, UK) cell lines were grown at 37oC, 5% CO2 in complete RPMI 1640, 10% 126 
fetal bovine serum (FBS), 1% Penicillin/Streptomycin (Invitrogen, Paisley UK). Human 127 
primary meningeal cells (Cat #1400) and choroid-plexus epithelial cells (Cat #1310) 128 
were obtained from ScienCell laboratories (Carlsbad, CA, USA) and cultured according 129 
to supplier’s instructions.  130 
Following informed consent, diagnostic bone marrow samples from children with BCP-131 
ALL underwent mononuclear cell enrichment using density-gradient centrifugation 132 
(Ficoll-Paque; GE Healthcare, Amersham, UK), cryopreservation in 10% 133 
DMSO/90%FBS and storage in liquid nitrogen until use. Samples originated from local 134 
institutions and the Leukaemia & Lymphoma Research (LLR) Childhood Leukaemia 135 
Cell Bank. Table 1 and supplementary table 1 list patient details. Use of human samples 136 
was approved by the West of Scotland Research Ethics Committee. ScienCell primary 137 
tissues are obtained following informed consent (www.sciencellonline.com/site 138 
/ethics.php). 139 
Xenotransplants 140 
JAX® NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) (Charles River, Europe), or NOD.Cg-141 
PrkdcscidIL2rgtm1Sug/JicTac (CIEA NOG®) (Taconic, Ry, Denmark) mice were kept in 142 
sterile isolators with autoclaved food, bedding and water. Xenotransplantation was 143 
performed at 6-10 weeks of age using intravenous (tail vein) or intrafemoral injections 144 
of up to 1x107 leukaemic cells, as previously described 11. Supplementary tables 2 and 3 145 
give details of individual experiments. Methods for serial dilution and sorting of 146 
leukaemic subpopulations have been published 11. Mice were humanely killed once they 147 
became unwell, had clinical evidence of leukaemia or significant weight loss. All 148 
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animal experiments were approved by Institutional Ethical Review Process Committees 149 
and performed under UK Home Office licences.  150 
Histology  151 
Murine heads were stripped of soft tissues, fixed in 10% Neutral Buffered Formalin 152 
(NBF) (CellPath, Powys, UK) and decalcified in Hilleman and Lee EDTA solution 153 
(5.5% EDTA in 10% formalin) for 2-3 weeks. Samples were processed as described 154 
previously 12. 155 
Anti-CD45 immunohistochemistry on paraffin-embedded sections was performed as 156 
previously described 13.  157 
Imaging used Axiostar-plus or AxioImager-M2 microscopes with Axiovision and Zen 158 
software (Carl Zeiss, Cambridge, UK). 159 
Cell retrieval 160 
Following terminal CO2 asphyxiation mice were perfused with phosphate-buffered 161 
saline (PBS) to eliminate peripheral blood contamination. Pilot experiments were 162 
performed comparing retrieval of leukaemic cells from the meninges alone vs. 163 
performing whole brain extracts of meninges and parenchyma. The former produced 164 
excellent yields of pure leukaemic cells, whilst the latter did not add to the yield and 165 
substantially reduced the viability and purity of the retrieved cells. Therefore, all 166 
experiments utilised direct retrieval of leukaemic cells from the leptomeninges by gentle 167 
scraping of the skull vault and vortexing the whole brain in PBS for 5 minutes. Femoral 168 
BM cells were retrieved by flushing with PBS. Spleen samples were collected by 169 
homogenising material through a cell strainer with PBS. 170 
Quantitative PCR 171 
RNA extraction, on-column DNase digestion, cDNA synthesis and custom designed 172 
Taqman low density arrays (TLDA) were performed as described previously 14. Two 173 
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reference endogenous control genes were included on the plate; TATA binding protein 174 
(TBP) and 18sRNA. Gene Assay IDs are given in supplementary data table 4. Both 175 
reference genes were validated according to MIQE guidelines15. Data were analysed 176 
using the ΔΔCT method using RQ Manager 1.2.4 software (Applied Biosystems, 177 
Paisley, UK). For gene expression arrays, arbitrary expression values were derived from 178 
the CT value as described previously 16. Gene expression assay IDs are given in 179 
Supplementary Table 4.  180 
Flow cytometry  181 
Cells were washed twice in PEF (0.5% FCS, 0.5mM EDTA in PBS), incubated with 182 
anti-human Fc-receptor binding inhibitor (eBioscience, Hatfield, UK) and then with 183 
directly conjugated antibodies (supplementary table 5). Viability staining used Viaprobe 184 
(BD Biosciences, Oxford, UK), or DRAQ7 (Biostatus, Shepshed, UK). Data were 185 
acquired on a MACSQuant flow cytometer (Miltenyi Biotec) and analysed using 186 
FlowJo 7.2.4 software (Tree Star Inc, Ashland, OR USA).  187 
Clonal tracking 188 
Primograft ALL blasts were lentivirally transduced and transplanted intrafemorally into 189 
NSG mice as described previously 17. Genomic DNA was extracted from splenic and 190 
leptomeningeal leukaemic blasts using a DNeasy kit (Qiagen). Analysis of lentiviral 191 
integration sites using non-restriction-based linear amplification mediated PCR 192 
(nrLAM-PCR) was described previously 18. The linear PCR step was performed using a 193 
biotinylated primer (Btn-GCACTGACAATTCCGTGGTGTT GTC) for 99 cycles (98 194 
°C for 10 s, 64 °C for 45 s and 72 °C for 15 s). The final amplification used two 195 
successive 30 cycle PCR reactions (98 °C for 10 s, 62 °C for 30 s and 72 °C for 2 min) 196 
with the following primers: Round 1 Fw GACCCGGGAGATCTGAATTC, Rev 197 
GCTACGTAACTCCCAACGAAG; Round 2: Fw AGTGGCACAGCAGTTAGG, Rev 198 
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GTGTGGAAAATCTCTAGCA). Illumina adaptors were added by PCR and samples 199 
were sequenced using an Illumina MiSeq. Reads were considered valid if they perfectly 200 
matched the expected vector flanking sequence. Sequences comprising less than 0.1% 201 
of the total were removed, and reads with truncations or mismatches within the 202 
remaining sequences were merged to create the final list.  203 
Statistics 204 
Student’s t-tests were used to analyse 2 parametric groups and Chi-squared tests were 205 
used to examine frequency of CNS infiltration. A p-value of ≤0.05 was considered 206 
significant. All analyses were performed using GraphPad Prism (La Jolla, CA, USA).  207 
 208 
RESULTS 209 
 210 
CNS engraftment in NSG mice is common and involves passage across the blood-CSF 211 
barrier 212 
To investigate the frequency and distribution of CNS engraftment, brains were 213 
examined from NSG mice xenografted with 29 different ALL samples (diagnostic BM 214 
samples and primary cells previously passaged through mice (primografts), see 215 
supplementary tables 1-3 for clinical and experimental details). CNS engraftment was 216 
observed in 23/29 patient samples (79%) across 13 different cytogenetic subtypes 217 
(Table 1). There was no difference in the frequency of CNS engraftment in primary BM 218 
samples vs. primografts (p= 0.303, Chi-squared test). CNS engraftment was seen in 219 
samples with both high and low risk clinical features (Table 2) and semi-quantitative 220 
scoring of the degree of CNS infiltration did not show clear differences between high 221 
and low risk samples (supplementary data table 2). Histopathology was consistent; 222 
showing early infiltration around the dural venous sinuses, plaques of disease in the 223 
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leptomeninges, relative sparing of the ventricles and absence of gross parenchymal 224 
involvement (Figure 2a-c). This indicates that ALL cells primarily transit the blood-CSF 225 
barrier (comprising the choroid plexus and the meningeal post-capillary venules) rather 226 
than the blood-brain barrier. Importantly, this histopathology closely resembles that 227 
observed in patients (Figure 2d) 4,19. 228 
Our original panel of primografts and primary samples mainly comprised CNS-1 229 
patients (table 1). Therefore, CNS-engrafting capacity appears to be more prevalent than 230 
suggested by CSF-cytospin status. However, since primograft samples have, a priori, 231 
shown successful engraftment in mice, there may have been a selection bias for 232 
aggressive leukaemias. To address this, we prospectively investigated CNS engraftment 233 
of BM-derived leukaemic cells from a CNS-3 patient (#5094) and 5 matched CNS-1 234 
controls (#4736, #5449, #6112, #5705 and #4630). These samples had unknown 235 
xenografting capability and all carried the good-prognosis translocation t(12;21). All 236 
samples engrafted in the BM whilst CNS infiltration was seen in the CNS-3 sample but 237 
also in 4/5 CNS-1 samples (Figure 2e).  238 
Together these observations indicate that the majority of diagnostic BCP-ALL BM 239 
samples contain cells capable of entering the CNS compartment, irrespective of initial 240 
CSF cytospin findings.  241 
 242 
Chemokine receptors do not drive CNS entry in BCP-ALL.  243 
In a murine model of T-ALL, expression of the chemokine receptor CCR7 determines 244 
CNS engraftment 20. In addition, a recent report has highlighted a possible association 245 
between CXCR3 expression and ALL migration to the CNS 21. Therefore, we 246 
investigated the role of chemokine receptors in directing leukaemic cells to the CNS 247 
compartment in our model. As shown in Figure 3 and Supplementary Figure 1 and 2 248 
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only CXCR3 and CXCR4 were consistently expressed on the cell surface with variable 249 
expression of CCR7 and CCR6 (figure 3a) and CXCR7 (supplementary figure 2). 250 
Comparison of chemokine receptor expression in two non-CNS homing primary 251 
samples (#4630 and #5969) showed the same pattern of chemokine receptor expression 252 
as 7 CNS homing primary samples (Figure 3a and Supplementary Table 6). Therefore, 253 
there was no apparent chemokine receptor expression signature that marked the ability 254 
to enter the CNS compartment. Next, we examined the repertoire of chemokine ligands 255 
expressed by human blood-CSF barrier tissues. Importantly, the CXCR3 ligand 256 
CXCL10, the CXCR4/CXCR7 ligand CXCL12 and the CCR6 ligand CCL20 were 257 
detected (Figure 3b), suggesting these pairings could be functionally important in ALL 258 
transit across this barrier. To investigate whether cells expressing high levels of any 259 
particular chemokine receptor were being positively selected for in the CNS 260 
compartment in vivo we compared expression profiles of leukaemic cells retrieved from 261 
the meninges and BM of engrafted mice. As seen in Figure 3c there was no evidence of 262 
positive selection for high-expressing sub-clones in the CNS, with leukaemic blasts 263 
showing similar chemokine receptor expression profiles at the two sites. Finally, given 264 
the importance of the chemokine receptor CXCR4 in BM engraftment, we went on to 265 
specifically interrogate the role of CXCR4 in CNS engraftment by utilising the CXCR4 266 
inhibitor AMD3100 in vivo. Interestingly, mice in the AMD3100 treated group showed 267 
a significant reduction in leukaemic burden in the liver and BM, but no reduction of 268 
CNS disease (Fig 3d and Supplementary Figure 3).  269 
Therefore, although chemokine receptors may play a permissive role in ALL transit 270 
across the blood-CSF barrier, single members do not appear to play an instructive role 271 
in determining localisation of leukaemic blasts in the CNS compartment. 272 
 273 
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CNS leukaemia initiating cells are frequent and not related to blast maturation status. 274 
Overall, the evidence of frequent CNS involvement and lack of chemokine receptor 275 
mediated selective trafficking to the CNS suggested to us that CNS-engrafting 276 
capability may be a generic property of BCP-ALL lymphoblasts rather than an acquired 277 
property of a rare sub-clone. To test this, we examined the frequency of cells within an 278 
individual leukaemia sample capable of CNS engraftment. Using a cohort of BCR-ABL 279 
and BCR-ABL-like (defined as an activated kinase gene expression profile which 280 
clusters with BCR-ABL on microarray but without a classical Philadelphia chromosome 281 
22) samples, cell suspensions were prepared containing 10, 100, 1000 or 1500 cells for 282 
intrafemoral transplantation (Figure 4a). The results of BM engraftment in this cohort of 283 
mice are already published 11. Figure 4a shows no relationship between cell number and 284 
likelihood of CNS engraftment and as few as 10 cells produced CNS disease in 5/6 285 
cases (Figure 4a and Supplementary Table 3).  286 
Since the ability to egress from the BM to the periphery is acquired during normal B-287 
cell development we next investigated whether CNS engraftment rates differed in 288 
mature vs. immature ALL subpopulations. Leukaemia propagating ability in childhood 289 
ALL does not appear to follow a hierarchical stem cell model 11,23 and indeed a stem 290 
cell-like transcriptional signature is seen in both CD34+ and CD34- ALL blasts 11. 291 
However, down-regulation of CD34 expression in ALL is associated with increased 292 
expression of B-cell differentiation genes 23 and diagnostic BCP-ALL samples contain 293 
blasts at different maturation stages 11. B-cell precursors were identified by gating on 294 
CD19 and then flow-sorted into CD34high (immature), CD34low (more mature), CD10low 295 
(immature), CD10high (more mature) and CD20low (immature), CD20high (more mature) 296 
populations. Sorted cells underwent limiting dilution and 10-1500 cells were injected 297 
intrafemorally (Supplementary Table 3). As seen in Figure 4b all fractions showed 298 
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CNS-engrafting capability and both immature and more mature B-cell subpopulations 299 
appeared to engraft in the CNS with equal competence.  300 
These experiments support our hypothesis that the ability to enter the CNS is not 301 
restricted to rare subclones but is instead a generic property of the majority of leukaemic 302 
cells present at original diagnosis.     303 
 304 
Clonal tracking experiments identify very similar clonal composition in CNS and 305 
periphery   306 
To lend further support to our hypothesis we performed clonal tracking of lentivirally 307 
marked #WB51 primograft cells, which carry the Philadelphia chromosome, and #L707 308 
cells which have a t(17;19) translocation. This allowed us to investigate both the clonal 309 
architecture of leukaemic subpopulations in the CNS and their relationship to cells in 310 
the periphery. This was achieved using a modified linear amplification-mediated PCR 311 
(LAM-PCR) protocol 18 to detect lentiviral integration sites in samples from the spleen 312 
and leptomeninges. Each integration site is unique, so can be used as a heritable marker 313 
to track the spread of individual clones (Figure 5a). Up to 10,000 cells were transplanted 314 
per mouse, with a maximum lentiviral transduction rate of 10% to limit the risk of 315 
multiple integrations in a single cell 24. Analysis of the most prevalent integrations in 316 
two mice per sample demonstrated that the CNS disease was polyclonal and very 317 
similar in clonal composition to the splenic disease (Figure 5b and Supplementary 318 
Figure 5). All integrations present in the spleen at >0.5% of the total population were 319 
also detectable in the meninges, demonstrating that all major clones had CNS engrafting 320 
capability. In the case of #WB51 femoral leukaemic cells were also analysed and again 321 
all detectable clones in the femur were also present in the CNS (supplementary figure 322 
5).        323 
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Together these experiments confirm our hypothesis that the ability to engraft in the CNS 324 
is a generic property of the bulk leukaemic population at initial diagnosis, rather than 325 
being due to acquisition of a metastatic phenotype by a rare sub-clone.  326 
 327 
DISCUSSION 328 
 329 
We have shown that CNS involvement is detectable in more than three-quarters of 330 
xenografts from diagnostic primary BCP-ALL samples and is seen with equal frequency 331 
in samples from patients with high- and low-risk cytogenetic and clinical features. 332 
These observations support a model whereby CNS relapse is determined by whether 333 
cells can adapt to the foreign microenvironment of the CNS and evade elimination by 334 
ALL-directed therapy and/or immunological surveillance (model 2), rather than whether 335 
individual clones present within a patients leukaemia acquire the ability to enter the 336 
CNS compartment (model 1) (illustrated in figure 1). The importance of this 337 
observation lies in the concept that CNS infiltration is likely to be present in the 338 
majority of patients at the time of diagnosis. Current cytological classification may lead 339 
to the erroneous impression that CNS-1 patients do not have any leukaemia in the CNS, 340 
and consequently that these children are at very low risk of CNS relapse..  341 
We acknowledge some limitations in the clinical interpretation of our work. Xenograft 342 
models are unlikely to completely faithfully recapitulate all the receptor-ligand 343 
interactions governing leukaemic engraftment in humans, although most trafficking 344 
molecules are highly conserved 25 and this limitation would be predicted to result in 345 
reduced rather than enhanced engraftment in xenografts. In addition, our limiting 346 
dilution and clonal tracking experiments were performed using high risk leukaemias 347 
which may more readily engraft in mice26-28. However, our original cohort of mice 348 
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showed frequent CNS involvement in both high and low-risk primary samples 349 
suggesting this is a universal property of BCP-ALL cells. Additional support for high 350 
rates of sub-clinical seeding of the CNS at the time of diagnosis comes from clinical 351 
observations. The use of more sensitive detection methods such as flow cytometry 7 and 352 
PCR 5,6 are able to detect occult CNS involvement in up to 40% of patients. In addition, 353 
prior to the era of routine CNS “prophylaxis”, 50-75% of children relapsed the CNS 1, 354 
usually within a couple of months of original diagnosis, suggesting occult CNS 355 
leukaemia was present from the outset. This rate of early CNS relapse in patients 356 
mirrors the rate of CNS infiltration in our xenograft model.  357 
Post-mortem histopathology from children with ALL demonstrates a pattern of CNS 358 
infiltration closely resembling our xenograft model 4. The earliest leukaemic infiltrates 359 
appear in the walls of superficial arachnoid veins, with progressive infiltration of the 360 
leptomeninges and subsequent extension into the deep arachnoid following the course 361 
of penetrating vessels.  Parenchymal infiltration is only seen in late stage disease, 362 
always accompanied by a breach of the pia-glial membrane 4. Therefore our results, 363 
along with these historical data, provide evidence for ALL cells primarily transiting the 364 
blood-CSF barrier rather than the blood-brain barrier. This is important when 365 
considering cellular trafficking, microenvironmental influences and drug 366 
pharmacokinetics as the leptomeninges and brain parenchyma are distinct physiological 367 
compartments 29. In addition, it highlights that commonly used in vitro models of the 368 
blood brain barrier are inappropriate to study mechanisms of CNS entry of leukaemic 369 
blasts. The close relationship of leukaemic cells to the dural sinuses is particularly 370 
intriguing given the recent description of lymphatic vessels in this area in mice 30.  Of 371 
note, our histology and the human post-mortem data 4 also show ALL blasts  adherent 372 
to meningeal stroma rather than free-floating in the CSF. This may explain why 373 
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sampling a small volume of CSF from the lumbar-spine may significantly underestimate 374 
CNS infiltration.  375 
We went on to examine whether chemokine receptors directed this migration across the 376 
blood-CSF barrier. In common with previous reports21,31-33 we show that BCP-ALL 377 
cells express CXCR3 and CXCR4 with some samples expressing CCR7, CCR6 and 378 
CXCR7. Corresponding chemokine ligands were expressed by blood-CSF barrier 379 
tissues. However, there was no evidence for positive selection of cells bearing these 380 
receptors within the CNS compartment. Previous work has shown that CXCR3 381 
inhibitors cause a global reduction in leukaemic engraftment in BM, spleen and CNS21. 382 
In contrast, we have shown that treatment with the CXCR4 inhibitor AMD3100 leads to 383 
a reduced disease burden in the liver and BM but no reduction in CNS infiltration 384 
suggesting CNS engraftment may be a CXCR4 independent niche. 385 
Our findings differ from results in T-ALL, where a single chemokine receptor ligand 386 
pairing (CCR7-CCL19) determined the ability of lymphoblasts to enter the CNS in a 387 
humanised murine model 20. Our findings may be due to differences in experimental 388 
models34, or the intrinsic biology of T- and B-cells; CCR7 expressing memory T-cells 389 
are the most abundant leukocyte to be found in normal CSF 35 and so it is perhaps not 390 
surprising that CCR7 expression enhances T-ALL entry into this site. 391 
Lastly, we investigated the subclonal composition of the CNS compartment. We found 392 
that CNS engrafting ability was a generic ability of leukaemic cells and that the clonal 393 
composition of CNS and splenic engrafting cells was remarkably similar. This suggests 394 
that CNS infiltrating ability is ubiquitous in BCP-ALL and strongly argues against our 395 
proposed model 1 and supports model 2 i.e. that CNS relapse originates from 396 
inadequate eradication of cells from this sanctuary site rather than selective entry 397 
(Figure 1). 398 
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Of note our studies do not exclude that individual cells/clones differ in their biological 399 
fitness to invade, proliferate and survive in the CNS but do indicate that CNS invasion 400 
is a generic ability of the leukaemic blasts. Differences in biological fitness may 401 
determine leukaemic load in the CNS and thus explain why some children have visible 402 
disease on CSF cytology and others do not, and may play a role in the likelihood of 403 
survival of cells in this compartment and the attendant risk of CNS relapse. Future 404 
efforts to investigate risk factors for CNS relapse should focus on advantageous 405 
leukaemic adaptations to this new niche, using approaches such as transcriptomics, 406 
metabolomics and proteomics. We and others have reported on the potential role of the 407 
cytokine interleukin-15 in promoting leukaemic cell survival in the hostile environment 408 
in the CSF 13,36. A recent report has highlighted a critical role for MER tyrosine kinase 409 
in promoting survival of t(1:19) positive ALL in the CNS37 and increased ICAM-138, 410 
SCD and Osteopontin39 expression have also been associated with CNS disease .  411 
Additional mechanisms of CNS relapse may relate to evasion of chemotherapy 40 or 412 
immune surveillance 34,41 at this site.  413 
Finally, our findings have important implications for the design of risk-adapted CNS 414 
therapy. Firstly, our studies indicate that the current dogma of CNS-directed therapy for 415 
all patients appears to have a rational scientific basis. Secondly, it is unlikely that 416 
chemokine receptor expression profiling will be a useful biomarker for CNS disease in 417 
BCP-ALL. Thirdly, identifying factors that enable long-term survival of cells in the 418 
CNS (which may also enhance long-term survival in the bone marrow) may be a better 419 
therapeutic strategy than attempts to block cell entry.  420 
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 560 
TABLES  561 
 562 
Table 1: Frequency of CNS engraftment in primary patient samples. Samples are 563 
grouped by cytogenetics. CNS engraftment was determined histologically and analysed 564 
blinded to patient details. TLP = Traumatic Lumbar Puncture with visible leukaemic 565 
blasts (+), without visible blasts (-). 566 
 567 
Table 2: Clinical risk factors for CNS engraftment. 568 
Clinical characteristics of patients whose samples infiltrated the CNS (CNS+) in the 569 
xenograft model, compared to those with no evidence of infiltration (CNS-). 570 
Cytogenetic high-risk group was defined according to the UKALL 2011 trial protocol. 571 
 572 
FIGURE LEGENDS 573 
Figure 1: Schematic representation of proposed mechanisms underlying CNS 574 
infiltration and subsequent relapse. In model 1 only some leukaemic cells acquire the 575 
ability to enter the CNS and the risk of CNS relapse depends on the presence or absence 576 
of a clone (shown in green) with the capacity to leave the bone marrow and enter the 577 
CNS. Different leukaemia subtypes may vary in this capacity with some (shown in blue) 578 
unable to enter the CNS compartment, others avidly traffic to the CNS (shown in 579 
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green), whilst some acquire this capacity in rare subclones (mixed purple, blue and 580 
green). In model 2 all leukaemic cells may have the ability to seed this compartment and 581 
sub-clinical CNS involvement at diagnosis may be universal and show little or no 582 
subclonal selection (model 2). In both cases, CNS relapse may also be determined by 583 
whether cells can adapt to the foreign microenvironment of the CNS and evade 584 
elimination by ALL-directed therapy and/or immunological surveillance (in this 585 
example green and/or yellow subclones have been selected for at relapse).  586 
 587 
Figure 2: Histological analysis of brains from xenografted mice. (a) Line drawing of 588 
a coronal section of murine brain showing approximate locations (zones) of images 589 
shown in (b)-(d). (b) Photomicrographs of H&E stained brain sections. Top image: low-590 
power view of cerebral cortex and leptomeninges (x5), bottom image: close-up of a 591 
central meningeal vessel (x40). Long thin arrow indicates leukaemic cells in the vessel 592 
wall. Black scale bar = 100µm (c) H&E (top row), and corresponding anti-human CD45 593 
(bottom row), staining of leukaemic deposits. Left-hand panel: cells surrounding the 594 
dural venous sinus (x20). Central panel: cells within choroid-plexus (x20). Right-hand 595 
panel: high-power view of meninges (x40). Black bar = 100µm (d) post-mortem image 596 
of grade 2 arachnoid leukaemia (zone ii) in a child with ALL – H&E (x33) – reproduced 597 
with permission from  Price and Johnson 4 (e) H&E of representative coronal sections 598 
(all zone iv) from mice engrafted with a CNS-3 sample and 5 matched CNS-1 controls 599 
(x40). Black bar = 50µm. 600 
In all images: thick black arrows mark the leukaemic infiltrate within the leptomeninges 601 
and black stars (*) mark leukaemic infiltrates within the calvarial bone marrow cavity. # 602 
denotes the sample identifier in Table 1. 603 
 604 
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Figure 3: Chemokine receptors and CNS engraftment. (a) Flow cytometry for 605 
chemokine receptor expression in BCP-ALL. Isotype control - shaded histogram, 606 
specific staining - open histogram. Samples names and associated translocations shown, 607 
CNS+ indicates the results of xenografting this sample into mice with Y= evidence of 608 
CNS engraftment and N= no evidence of CNS engraftment (b) Quantitative PCR for 609 
chemokine ligand expression by cultured human primary meningeal cells (white bars) 610 
and choroid plexus epithelial cells (black bars) (both passage 3). Arbitrary expression 611 
values were derived from ΔCT. (c) Primary ALL cells from 1 CNS-3 patient (open 612 
symbols) and 4 CNS-1 matched controls (closed symbols) were retrieved from BM and 613 
meninges of xenografted mice and analysed by flow cytometry. Contaminating murine 614 
cells were excluded by gating on human CD45. 105 events were analysed where 615 
possible. Data represent adjusted mean fluorescence intensity (MFIspecific - MFIisotype) of 616 
live leukaemic cells (huCD45+/Draq7-). Bars represent means of adjusted MFIs. 617 
Differences between CNS and BM expression were analysed using two-tailed paired 618 
student t-tests. (d) Leukaemic infiltration in NSG mice engrafted with REH-luciferase-619 
GFP expressing cells and treated with the CXCR4 inhibitor AMD3100 or PBS control. 620 
Left hand panel shows leukaemic engraftment in the bone marrow as measured by 621 
numbers of GFP-positive cells (REH-luciferase GFP) on flow cytometry. Data show 622 
mean ± SEM in n=7 and n=6 mice for PBS and AMD3100 groups respectively, 623 
analysed by an unpaired student t-test, ***p<0.001.Central panel shows liver infiltration 624 
quantified by counting human-CD45+ cells (brown DAB-stained cells) in 8 random 625 
fields of view per section. Data show mean ± SEM for n=4 and n=5 mice in PBS and 626 
AMD3100 groups respectively, analysed by an unpaired student t-test, **p<0.01.  Right 627 
hand panel shows histological analysis of murine brains from xenografts (n=5 mice in 628 
each group). Each brain was divided into 5 segments and sections were cut from each 629 
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segment, the maximal depth of meningeal infiltrates was recorded for each section using 630 
Axiovision Rel 4.3 software (Carl Zeiss). Data show mean ± SEM. Representative 631 
histology and IVIS imaging from these mice along with full experimental details are 632 
provided in Supplementary Figure 3. 633 
 634 
Figure 4: CNS engraftment of sorted sub-populations of leukaemic blasts. Sorted 635 
and unsorted leukaemic blasts from 6 primografts (#4540, #M120, #WB51, #HV101, 636 
#737c and #758b), were injected intrafemorally, at limiting dilutions into the femurs of 637 
1-4 mice each. CNS involvement was assessed histologically following transplantation 638 
of; (a) 10-1500 cells, or (b) different immunophenotypic sub-populations of leukaemic 639 
blasts. Black bars represent the number of mice in each experimental group with 640 
evidence of CNS involvement (CNS+) on histology. White bars represent number of 641 
mice without any visible CNS infiltration (CNS-). Individual results of mice injected 642 
with each cell number/immunophenotypic subpopulation for the different primografts 643 
are given in Supplementary Table 3.  644 
  645 
Figure 5: Subclonal composition of CNS and splenic compartments.  (a) Schematic 646 
of experimental design. (b) Clonal composition of CNS (leptomeninges) and splenic 647 
compartments of mice transplanted with primograft samples #WB51 and #L707. Pie 648 
charts show frequencies of most prevalent integrations in paired CNS and spleen 649 
samples from two mice per sample. Pie chart colours are unique to each mouse spleen-650 
meninges pair and do not represent the same clones between different mice. 651 
Corresponding tables of integration site frequencies for each mouse are given in 652 
Supplementary Figure 5. 653 
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Table 1 
 
Cytogenetic sub-group   Sample ID  Patients CNS status at 
diagnosis (cytospin)  
No of mice with CNS 
engraftment 
  t(12;21)  #4630  CNS-1  0/3  
#4736  CNS-1  2/2 
#5449  CNS-1  1/2 
#5094  CNS-3  3/3 
#6112 CNS-1 1/2 
#5705  CNS-1  2/2 
  High Hyperdiploid #L779 CNS-1     5/5 
#5969 CNS-1 0/2 
#6294  CNS-1  0/1  
  t(7;9)dic(9;20)  #21819  CNS-1  1/1 
  t(9;22)  #4540  TLP+  2/2 
#M120  TLP-  2/2 
#WB51  CNS-1  7/7 
  t(9;22), del 9p  #HV101  TLP+  2/2 
  Bcr-abl like #737c  CNS-1  12/13 
#758b  CNS-1  3/5 
  t(11q23)   #6240 CNS-3  3/3 
  #5655 CNS-1 3/3 
  #4861  CNS-1  0/2 
  t(1;19)    #L910  CNS-1  1/1 
#BH01  CNS-1  0/3  
  t(8;14) – non-Burkitt    #20580  CNS-1  4/5 
  iAmp21    #L868  CNS-1  7/7 
#L904  CNS-1  0/2  
  t(17;19)  #L707  CNS-1  2/2 
  IgH translocation #20951 CNS-1 3/3 
  CRLF2 deletion #11538 CNS-1 4/4 
  No result  #L897  CNS-1  4/4 
#L920  CNS-1  1/1 
  13 cytogenetic groups  29 patient samples  2 CNS-3, 24 CNS-1, 3 
TLP,             
75/94 mice and 23/29 
primary samples 
engrafted in CNS  
 
 
 
 
  
  Williams et al. 
 26 
 
 
Table 2 
 
Characteristic  Category  CNS +ve  CNS -ve  p-value*     
     
n=23     n=6     
      n  %   n  %  
Age  <10 year  17  (77)  5  (23)  0.631  
 
>10 years  6  (86)  1  (10)  
 Sex  Male  10  (90)  1  (10)  0.228  
 
Female  13  (70)  5  (30)  
 WCC  WCC <100  15  (80)  4  (20)  0.947  
 
WCC >100  8  (80)  2  (20)  
 CNS status  CNS-1  18  (80)  6  (20)  0.665  
 
CNS-3  2  (100)  0  (0)  
 
 
TLP+  2  (100)  0  (0)  
 
 
TLP-  1  (100)  0  (0)  
 Cytogenetic 
risk  Low risk  6  (67)  3  (33)  0.455 
 High risk  8 (80)  2  (20)   
 Others  9 (90)  1 (10)   
Outcome  CCR**  15  (70.0)  6  (30)  0.237  
 
Relapse  7  (100)  0  (0)  
 
 
TRM  1  (100)  0  (0)  
 *calculated using chi-square test  
**continuous complete remission until last follow-up  
Cytogenetic low risk  t(12;21), High Hyperdiploid  
   Cytogenetic high risk  t(9;22), iAMP21, t(17;19), 11q23 
Others  t(7;9)dic(9;20), t(8;14) – non-Burkitt, bcr-abl-like, IgH translocation, 
CRLF2 deletion, no result  
 
 
 
 
